• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FTC approves Baxter’s $625m Claris buyout, with conditions

July 21, 2017 By Sarah Faulkner

BaxterThe Federal Trade Commission approved Baxter‘s (NYSE:BAX) $625 million acquisition of Claris Lifesciences‘ (BOM:533288) injectable drug biz, but mandated that the companies divest two drugs products – an antifungal agent, fluconazole, and intravenous milrinone.

The FTC filed a complaint saying that the original deal would likely reduce competition in the U.S. for fluconazole since Baxter and Claris represent two of the four significant competitors selling fluconazole in saline intravenous bags. Combined, they hold an estimated market share of 60%, according to the FTC.

Similarly, the agency said that the deal would reduce future competition in the U.S. for intravenous milrinone, since the drug is only sold by three companies, including Baxter. Claris has an application pending approval with the FDA for its version of the product.

“In generic pharmaceutical markets like those at issue here, reducing the number of significant suppliers from four to three is likely to harm consumers through higher drug prices,” the FTC wrote. “Similarly, in a market with three current suppliers, depriving consumers of a pending, fourth viable supplier is likely to maintain prices at higher levels than would have occurred had the expected entry occurred.”

According to Reuters, the companies have agreed to meet the FTC’s conditions.

The merger deal was announced in December and is expected to close in the 2nd half of next year. Deerfield, Ill.-based Baxter said it plans to pay for the acquisition with cash on hand, debt or a combination of both.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Baxter International, Claris Lifesciences

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS